ChipCare is a privately held, for profit, corporation developing a handheld cell analyzer based on mobile technology. Its vision is to become a global leader in developing and providing point-of-care (POC) testing solutions for global health.
ChipCare’s mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. Continue reading
CCRM’s mission is to create and sustain a global nexus for Regenerative Medicine (RM) commercialization by unifying dynamic business leadership with high value innovative translational technology platforms based on demonstrated excellence in fundamental stem cell and biomaterial science.
- Hospital for Sick Children Research Institute, Toronto, Ontario
- McMaster University, Hamilton, Ontario
- Mount Sinai Hospital Samuel Lunenfeld Research Institute, Toronto, Ontario
- Ottawa Hospital Research Institute, Ottawa, Ontario
- University Health Network, Toronto, Ontario
- University of Toronto, Toronto, Ontario (HOST INSTITUTION)
Established in July 2008 with a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd (formerly Avidex/MediGene) and exclusively licensed for T cell therapy. Backed by private investors, Adaptimmune is now in the clinic in the US, in HIV as well as multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.
Adaptimmune’s Mission Statement
Adaptimmune’s mission is to develop disruptive therapy for serious disease using engineered T cells. The Company’s core technology is the development of affinity-enhanced T cell receptors (TCR) for use in adoptive T cell therapy.
The Adaptimmune product is a T cell expressing a modified TCR to recognize a tumour antigen (epitope) associated with a HLA molecule.
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company was founded in 2002 based on world-leading research at the University of Oxford. The European headquarters are located in Abingdon, UK and the North American headquarters are located in Marlborough, MA USA.
T-Cell Xtend is an antibody complex directed against specific cell surface antigens
on human blood cells
• T-Cell Xtend cross-links selected white cells, that may interfere with ELISPOT
assays, with red blood cells
• This cross-linking increases the density of selected cells so that they form a pellet
when applied to a density gradient
The use of T-Cell Xtend allows the T-SPOT®.TB assay to be performed on blood samples up to 32 hours after venepuncture without any change in accuracy of the test.
Kela Medical Inc. harnesses the power of innovation and technology to pioneer leading-edge solutions, and demonstrate the value of a fully accessible personal health record to individuals, physicians, and practitioners of the healthcare industry.
pHR CARD SYSTEM
Kela Medical Inc. introduces the pHR Card – Personal Health Record Card. The system uses patented* technology to provide economical solutions for physicians and patients to create, access, and maintain electronic medical records.
HEALTHCARE IT SERVICES
Kela Medical Inc. provides a healthcare IT service specifically designed for private medical practices. Our company is dedicated to delivering comprehensive solutions with the strength to make a difference in how you provide healthcare.
Sortable’s decision engine helps you make the right choice. Our engine powers niche markets to help visitors sort, compare and purchase consumer products.
Sortable is launching http://www.TabletRocket.com a tablet comparison website that makes it easier to research the best tablet by comparing tablet specs, performance tests, pricing info and reviews from around the web in one place. We’ve been working to replace the old tablets feature on Sortable with a new and improved site dedicated to tablets so enjoy!
SEE WHAT ABCAM CAN DO FOR YOUR LAB?
Over the last 15 years, Abcam has remained committed to supporting scientists on their quest for discovery. We’ve focused on continually improving our high quality products and services by improving our global delivery times, enhancing our customer service offering, and increasing the validation information of our products. We’ve also expanded our product range beyond primary antibodies to include secondaries, proteins and peptides, lysates, biochemicals, immunoassays and other kits.
Affinium is a specialty pharmaceutical company developing a new class of antibiotics that targets FabI in the bacterial fatty acid synthesis pathway AFN-1252, the lead clinical compound, is a first-in-class antibiotic for both oral and IV treatment of staphylococcal infections. AFN 1252 has highly potent activity only against staphylococci, including MRSA and all other drug resistant strains, and therefore may protect from off-target, negative effeccts of broader spectrum agents.
Joon Kim founded Apollonia Health, an oral healthcare biotech company
Apollonia Health researches and develops innovative oral hygiene products that can safely and selectively eliminate cavity causing bacteria.
The company manufactures revolutionary oral healthcare products made only with naturally occurring ingredients. Because of this, their products can be used safely by children.